These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39489506)

  • 21. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
    Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
    Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
    Francuzik W; Alexiou A; Worm M
    Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
    [No Abstract]   [Full Text] [Related]  

  • 23. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres.
    Garritsen FM; Roekevisch E; van der Schaft J; Deinum J; Spuls PI; de Bruin-Weller MS
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1905-12. PubMed ID: 25752497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis.
    Anand P; Schneeweiss S; Mostaghimi A; Schneeweiss MC
    Pharmacoepidemiol Drug Saf; 2023 May; 32(5):567-576. PubMed ID: 36527432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atopic dermatitis: phototherapy and systemic therapy.
    Davis DM; Borok J; Udkoff J; Lio P; Spergel J
    Semin Cutan Med Surg; 2017 Sep; 36(3):118-123. PubMed ID: 28895958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dupilumab for treatment of atopic dermatitis.
    Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
    Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
    Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
    J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis.
    Narla S; Silverberg JI; Simpson EL
    J Am Acad Dermatol; 2022 Mar; 86(3):628-636. PubMed ID: 34126094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study.
    Hosseini-Ashrafi M; Clayton TH; Herring M; Herety N; Arkwright PD
    Clin Exp Dermatol; 2024 May; 49(6):578-583. PubMed ID: 38189448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective.
    Johansson E; Giovannitti M; Mezzetti M; Lu N; Sabatino S
    J Med Econ; 2023; 26(1):1155-1166. PubMed ID: 37674383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
    Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD).
    de Bruin-Weller M; Pink AE; Ferrucci SM; Patrizi A; Svensson A; Schuttelaar MLA; Tauber M; Ardeleanu M; Jayawardena S; Daoud M
    J Dermatolog Treat; 2022 Aug; 33(5):2565-2570. PubMed ID: 35255779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
    Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
    Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient.
    Giavina-Bianchi M; Rizzo LV; Giavina-Bianchi P
    Allergol Immunopathol (Madr); 2020; 48(6):792-797. PubMed ID: 32249095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
    Blauvelt A; Wollenberg A; Eichenfield LF; Zhang H; Sierka D; Khokhar FA; Vakil J; Shabbir A; Marco AR; Cyr SL
    Adv Ther; 2023 Jan; 40(1):367-380. PubMed ID: 36318387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina].
    Máspero J; Angles MV; Ardusso L; Brancciforte M; Castro C; Cruz Iturrieta C; Chouela E; De Gennaro MS; Fernández Bussy R; Galimberti ML; Galimberti RL; Gattolin G; Luna PC; Magariños G; Marini MG; Maskin M; Plafnik R; Raimondo N; Russo JP; Sevinsky L; Stringa MF
    Rev Fac Cien Med Univ Nac Cordoba; 2020 Jun; 77(2):94-99. PubMed ID: 32558511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological management of atopic dermatitis in the elderly.
    Howell AN; Ghamrawi RI; Strowd LC; Feldman SR
    Expert Opin Pharmacother; 2020 May; 21(7):761-771. PubMed ID: 32100586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
    Simpson EL; Paller AS; Siegfried EC; Boguniewicz M; Sher L; Gooderham MJ; Beck LA; Guttman-Yassky E; Pariser D; Blauvelt A; Weisman J; Lockshin B; Hultsch T; Zhang Q; Kamal MA; Davis JD; Akinlade B; Staudinger H; Hamilton JD; Graham NMH; Pirozzi G; Gadkari A; Eckert L; Stahl N; Yancopoulos GD; Ruddy M; Bansal A
    JAMA Dermatol; 2020 Jan; 156(1):44-56. PubMed ID: 31693077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal utilization of systemic immunomodulators before and after dupilumab approval in children with atopic dermatitis.
    Anand P; Schneeweiss S; Mostaghimi A; Schneeweiss MC
    Pediatr Dermatol; 2023 Jan; 40(1):132-134. PubMed ID: 36403606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.